Big Pharma Faces R&D, Regulatory, Political Gridlock Issues

Aug. 14, 2012
According to Burrill & Company’s 26th Annual Report on the Life Sciences Industry—“Biotech 2012: Innovating in the New Austerity”—in 2011, “several drug companies sought to cut R&D [research and development] expenses.”

San Francisco-based Burrill & Company (www.burrillandco.com), which released that report at the 2012 BIO International Conference in Boston, on June 18-21, believes cuts and decreased revenues are acknowledgement that R&D spending didn’t yield an adequate return on investment.

So, Burrill asks, “How will pharmaceutical companies create the new products they need to sustain themselves?” Big Pharma’s answer, Burrill notes, is what much of manufacturing has done and continues to do: essentially, try to do more with less.

An on-scene survey of biotech executives from 169 companies, at the same convention—sponsored by Washington, D.C.-based Biotechnology Industry Organization (www.bio.org)—also identified lack of available capital as a manufacturing-performance issue.  Through BIO’s backing, Alexandria, Va.-headquartered Public Opinion Strategies (www.pos.org) and D.C.-based Hart Research Associates (www.hartresearch.com) conducted the survey.

The majority of interviewed executives also said federal regulation hinders biotechnology’s performance. Making the federal regulatory approval process more efficient and transparent, without compromising consumer safety, would be helpful, 82 percent of the respondents said. And, 58 percent of the respondents said federal government regulation has had a negative impact.

But politics also presents headaches. One in four respondents identified federal, state and local taxes on the industry as a difficult challenge over the next decade. Perhaps not surprising these days, about three of four respondents cited partisan gridlock in Washington, D.C., as critical concern over the next five to 10 years.

Sponsored Recommendations

Rock Quarry Implements Ignition to Improve Visibility, Safety & Decision-Making

George Reed, with the help of Factory Technologies, was looking to further automate the processes at its quarries and make Ignition an organization-wide standard.

Water Infrastructure Company Replaces Point-To-Point VPN With MQTT

Goodnight Midstream chose Ignition because it could fulfill several requirements: data mining and business intelligence work on the system backend; powerful Linux-based edge deployments...

The Purdue Model And Ignition

In the automation world, the Purdue Model (also known as the Purdue reference model, Purdue network model, ISA 95, or the Automation Pyramid) is a well-known architectural framework...

Creating A Digital Transformation Roadmap Using A Unified Namespace

Digital Transformation has become one of the most popular buzzwords in the automation industry, often used to describe any digital improvements to industrial technology. But what...